Randomized Phase II Trial of Capecitabine and Lapatinib with or without IMC-A12 (Cituxumumab) in Patients with HER2-Positive Advanced Breast Cancer Previously Treated with Trastuzumab and Chemotherapy: NCCTG N0733 (Alliance)
Author:
Funder
Foundation for the National Institutes of Health
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology
Link
https://link.springer.com/content/pdf/10.1007/s10549-021-06221-8.pdf
Reference50 articles.
1. Siegel RL, Miller KD, Jemal A (2016) Cancer statistics. Ca Cancer J Clin 66(1):7–30. https://doi.org/10.3322/caac.21332
2. Pinto AC, Ades F, de Azambuja E, Piccart-Gebhart M (2013) Trastuzumab for patients with HER2 positive breast cancer: delivery, duration and combination therapies. Breast (Edinburgh, Scotland) 22(Suppl 2):S152-155. https://doi.org/10.1016/j.breast.2013.07.029
3. O’Sullivan CC, Smith KL (2014) Therapeutic considerations in treating HER2-positive metastatic breast cancer. Curr Breast Cancer Reports 6(3):169–182. https://doi.org/10.1007/s12609-014-0155-y
4. Zardavas D, Cameron D, Krop I, Piccart M (2013) Beyond trastuzumab and lapatinib: new options for HER2-positive breast cancer. Am SocClinOncolEduc Book Am SocClinOncol Meet. https://doi.org/10.1200/EdBook_AM.2013.33.e2
5. Nahta R, Yuan LX, Zhang B, Kobayashi R, Esteva FJ (2005) Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Can Res 65(23):11118–11128. https://doi.org/10.1158/0008-5472.can-04-3841
Cited by 9 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Extracellular Interactors of the IGF System: Impact on Cancer Hallmarks and Therapeutic Approaches;International Journal of Molecular Sciences;2024-05-29
2. Trastuzumab-emtansine versus other anti-HER2 regimens in early or unresectable or metastatic HER2 positive breast cancer: systematic review and network meta-analysis;Revista Peruana de Medicina Experimental y Salud Pública;2024-05-08
3. The Relationship between IGF Pathway and Acquired Resistance to Tyrosine Kinase Inhibitors in Cancer Therapy;Frontiers in Bioscience-Landmark;2023-08-11
4. Insulin-like growth factor-1 receptor crosstalk with integrins, cadherins, and the tumor microenvironment: sticking points in understanding IGF1R function in cancer;Endocrine-Related Cancer;2023-07-25
5. Targeting signaling pathways in osteosarcoma: Mechanisms and clinical studies;MedComm;2023-07-10
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3